Lasa Supergenerics Ltd
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations (Operational Tracking) INR Million |
|
|||||||||||
| Export Contribution to Revenue % |
||||||||||||
| Number of Granted Patents Number |
||||||||||||
| Number of Customers Number |
||||||||||||
| Capacity Utilization % |
||||||||||||
| Production Capacity (Rated/Output) TPA |
||||||||||||
| Global Market Share - Albendazole % |
||||||||||||
| Total Volumetric Capacity TPA |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual secretarial compliance report for FY2025-26 cites five SEBI/LODR delays and fines totalling about Rs.2.03 lakh.
-
Related Party Transaction As On 31St March 2026
29 May - Related party transaction disclosure for quarter and year ended March 31, 2026; total value 35.36.
-
Integrated Filing As On March 31, 2026
29 May - FY26 audited results approved; auditors issued modified opinion, citing fire damage, impairment issues and GST demands of Rs. 38.11 crore.
-
Board Meeting Outcome for Revised Outcome Of Board Meeting For Quarter Ended 31 March 2026
29 May - Board approved FY26 audited results; auditor issued qualified opinion after fire-related plant damage and GST demands.
-
Board Meeting Outcome for Outcome Of Board Meeting For Quarter Ended March 31 St 2026
29 May - Q4 FY26 results approved on 29 May 2026; auditors issued qualified opinion over fire damage and GST demands.
Annual reports
Concalls
-
Aug 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Oct 2020TranscriptAI SummaryPPT
-
Jun 2020Transcript PPT
-
Jun 2018Transcript PPT
-
Feb 2018TranscriptAI SummaryPPT
-
Dec 2017Transcript PPT
Business Overview:[1]
LSL is a part of Lasa group which is a veterinary API manufacturing entity. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary APIs with one of the largest production capabilities in India. It covers entire animal and human healthcare value chain—from discovery-to-delivery, in research, manufacturing and global marketing. Company has backward integrated its key molecules—from discovery research up to full-scale bulk production